-

Shareholder Alert: Robbins LLP Announces Trulieve Cannabis Corp. (TCNNF) Sued for Misleading Shareholders

SAN DIEGO & QUINCY, Fla.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Trulieve Cannabis Corp. (OTC: TCNNF) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 25, 2018 and December 17, 2019. Trulieve operates a medical marijuana company.

If you suffered a loss as a result of Trulieve's misconduct, click here.

Trulieve Cannabis Corp. (TCNNF) Accused of Misleading Shareholders

According to the complaint, in September 2018, Trulieve filed a listing statement following its merger with Schyan Exploration Inc., lauding its high-yield indoor cultivation facilities and techniques that gave Trulieve impressive cultivation and greenhouse capacity. Throughout the relevant period, Trulieve touted substantial increases in gross profit in its biological asset transformation with margins of 130% growth on average, which the Company attributed to "increased gain on biological assets and increased retail sales." Then, on December 17, 2019, Grizzly Research published a report revealing that rather than using the high-quality indoor production the Company consistently touted, in reality, the vast majority of the Company's marijuana was produced in low quality hoop houses, therefore making its gross margins on biological assets excessive and inflated. Additionally, the report revealed that Trulieve had failed to disclose related party real estate transactions that resulted in substantial gains for the related party. On this news, shares of Trulieve fell almost 13%, to close at $10.40.

Trulieve Cannabis Corp. (TCNNF) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

OTCQX:TCNNF

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom